Gyre Therapeutics (GYRE) Revenue Growth (3y) (2013 - 2026)
Gyre Therapeutics (GYRE) Revenue Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 10.17% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.76% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 979.48% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 42.02% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -91.03% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.80% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 59.40% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 76.62% |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | -0.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.26% |
| Mar 31, 2026 | -3.33% |
| Dec 31, 2025 | -28.44% |
| Mar 31, 2025 | 202.86% |
| Dec 31, 2024 | 126.39% |
| Sep 30, 2024 | 122.98% |
| Jun 30, 2024 | 181.40% |
| Mar 31, 2024 | 164.58% |
| Dec 31, 2023 | 137.32% |
| Sep 30, 2023 | 229.83% |
| Jun 30, 2023 | 160.56% |
| Mar 31, 2023 | 15.06% |
| Mar 31, 2021 | 525.31% |
| Dec 31, 2020 | 85.54% |
| Sep 30, 2020 | 41.08% |
| Jun 30, 2020 | 146.28% |
| Mar 31, 2020 | 292.34% |
| Mar 31, 2018 | -79.25% |
| Dec 31, 2017 | -22.07% |
| Sep 30, 2017 | -16.54% |